港股生物医药板块狂飙，新股恒瑞医药、MIRXES均涨超30%

新浪港股2025-05-23

5月23日消息，港股生物技术、药品股多股大涨，其中，今日正式上市的恒瑞医药和MIRXES分别涨超30%、36%。歌礼制药、博安生物、科伦博泰生物、凯莱英、信达生物等个股纷纷大涨。　　消息面上，一方面受益于三生制药与辉瑞达成的PD-1/VEGF双抗SSGJ-707全球权益合作的消息催化，中国创新药企通过技术授权（License-out）加速融入全球产业链，市场对于国产创新药出海预期被放大。　...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2537742369?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-23 09:35","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2537742369","market":"hk","top_or_hot":-1,"title":"港股生物医药板块狂飙，新股恒瑞医药、MIRXES均涨超30%","media":"新浪港股","content":"<div>\n<p>5月23日消息，港股生物技术、药品股多股大涨，其中，今日正式上市的恒瑞医药和MIRXES分别涨超30%、36%。歌礼制药、博安生物、科伦博泰生物、凯莱英、信达生物等个股纷纷大涨。\n\n\n　　消息面上，一方面受益于三生制药与辉瑞达成的PD-1/VEGF双抗SSGJ-707全球权益合作的消息催化，中国创新药企通过技术授权（License-out）加速融入全球产业链，市场对于国产创新药出海预期被放大。\n　...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/2025-05-23/doc-inexpeui1008253.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股生物医药板块狂飙，新股恒瑞医药、MIRXES均涨超30%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股生物医药板块狂飙，新股恒瑞医药、MIRXES均涨超30%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-23 09:35 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/2025-05-23/doc-inexpeui1008253.shtml><strong>新浪港股</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>5月23日消息，港股生物技术、药品股多股大涨，其中，今日正式上市的恒瑞医药和MIRXES分别涨超30%、36%。歌礼制药、博安生物、科伦博泰生物、凯莱英、信达生物等个股纷纷大涨。\n\n\n　　消息面上，一方面受益于三生制药与辉瑞达成的PD-1/VEGF双抗SSGJ-707全球权益合作的消息催化，中国创新药企通过技术授权（License-out）加速融入全球产业链，市场对于国产创新药出海预期被放大。\n　...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/2025-05-23/doc-inexpeui1008253.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1969619763.USD","symbol_name":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","start_time":0,"source_url":"https://finance.sina.com.cn/stock/hkstock/2025-05-23/doc-inexpeui1008253.shtml","article_id":"2537742369","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537742369","pubTimestamp":1747964100,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"5月23日消息，港股生物技术、药品股多股大涨，其中，今日正式上市的恒瑞医药和MIRXES分别涨超30%、36%。歌礼制药、博安生物、科伦博泰生物、凯莱英、信达生物等个股纷纷大涨。　　个股方面，恒瑞医药在公开发售阶段获454.85倍认购，国际配售阶段获17.09倍认购。据恒瑞医药披露的2024年年度报告，2024年公司实现营业收入279.85亿元，同比增长22.63%；归属于上市公司股东的净利润63.37亿元，同比增长47.28%。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"161726":"生物医药","399441":"生物医药","600276":"恒瑞医药","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","YANG":"三倍做空富时中国ETF-Direxion","07226":"南方两倍做多恒科","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK0060":"抗癌","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","02629":"MIRXES-B","HSCEI":"国企指数","BK0196":"行业龙头","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK0239":"医药制造","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","HSTECH":"恒生科技指数","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK0183":"MSCI概念","BK4614":"Manus概念股","01276":"恒瑞医药","BK0188":"融资融券","BK0012":"证金概念","BK0028":"国家队","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC"},"translate_title":"The biomedical sector of Hong Kong stocks soared, and new stocks Hengrui Medicine and MIRXES both rose by more than 30%","themeId":"92258637d6ff1e9cb4f4844790de8572","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161726":1,"399441":1,"600276":1,"07226":1,"YANG":1,"02629":1,"HSCEI":1,"HSTECH":1,"01276":1},"content_text":"5月23日消息，港股生物技术、药品股多股大涨，其中，今日正式上市的恒瑞医药和MIRXES分别涨超30%、36%。歌礼制药、博安生物、科伦博泰生物、凯莱英、信达生物等个股纷纷大涨。\n\n\n　　消息面上，一方面受益于三生制药与辉瑞达成的PD-1/VEGF双抗SSGJ-707全球权益合作的消息催化，中国创新药企通过技术授权（License-out）加速融入全球产业链，市场对于国产创新药出海预期被放大。\n　　此外从医药基本面的角度，机构普遍认为，2025年是行业“三个元年”——收入放量元年（医保谈判后产品加速放量）、盈利跨越元年（成批企业进入盈利期）、估值抬升元年（支付端改善拉长估值周期）。导致资金的风格偏好正从AI、机器人等赛道向创新药漂移，筹码结构改善显著。\n　　个股方面，恒瑞医药在公开发售阶段获454.85倍认购，国际配售阶段获17.09倍认购。据恒瑞医药披露的2024年年度报告，2024年公司实现营业收入279.85亿元，同比增长22.63%；归属于上市公司股东的净利润63.37亿元，同比增长47.28%。\n　　MIRXES-B全球发售4662万股股份，每股发售价23.3港元，全球发售净筹约8.8亿港元，其中香港公开发售获25.51 倍认购，国际发售获0.98倍认购。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：王若云","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2537742369","isCrawlerRequest":true}